BACKGROUND: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. METHODS: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. RESULTS: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. CONCLUSION: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.
BACKGROUND: Existing estimates of the costs of antimicrobial resistance exhibit broad variability, and the contributing factors are not well understood. This study examines factors that contribute to variation in these estimates. METHODS: Studies of the costs of resistant infections (1995-2009) were identified, abstracted, and stated in comparable terms (eg, converted to 2007 U.S. dollars). Linear regressions were conducted to assess how costs incurred by patients with resistant infections versus those incurred by uninfected or susceptible-organism-infected controls varied according to (1) costs incurred by control subjects; (2) study population characteristics; (3) methodological factors (eg, matching); and (4) length of stay. RESULTS: Estimates of difference in costs incurred by patients with resistant infections versus patients without resistant infections varied between $-27,609 (control costs exceeded case costs) and $126,856. Differences were greater when the costs incurred by control subjects were higher (ie, when the underlying cost of care was high). Study-adjusted cost differences were greater for bloodstream infections (vs. any other infection site), for studies that reported median (vs. mean) costs, for studies that reported total (vs. postinfection or infection-associated) costs, for studies that used uninfected (vs. susceptible-organism-infected) controls, and for studies that did not match or adjust for length of stay before infection. CONCLUSION: The cost of antimicrobial resistance seems to vary with the underlying cost of care. Increased costs of resistance are partially explained by longer length of stay for patients with resistant infections. Further research is needed to assess whether interventions should be differentially targeted at the highest cost cases.
Authors: Heather L Evans; Shayna N Lefrak; Jason Lyman; Robert L Smith; Tae W Chong; Shannon T McElearney; Alison R Schulman; Michael G Hughes; Daniel P Raymond; Timothy L Pruett; Robert G Sawyer Journal: Crit Care Med Date: 2007-01 Impact factor: 7.598
Authors: Ebbing Lautenbach; Mark G Weiner; Irving Nachamkin; Warren B Bilker; Angela Sheridan; Neil O Fishman Journal: Infect Control Hosp Epidemiol Date: 2006-08-21 Impact factor: 3.254
Authors: John A Weigelt; Benjamin A Lipsky; Ying P Tabak; Karen G Derby; Myoung Kim; Vikas Gupta Journal: Am J Infect Control Date: 2009-11-03 Impact factor: 2.918
Authors: Michelle Gearhart; Jill Martin; Steve Rudich; Mark Thomas; Dave Wetzel; Joseph Solomkin; Michael J Hanaway; Jaime Aranda-Michel; Fred Weber; Leslie Trumball; Maryetta Bass; Ed Zavala; E Steve Woodle; Joseph F Buell Journal: Clin Transplant Date: 2005-12 Impact factor: 2.863
Authors: Sara E Cosgrove; Youlin Qi; Keith S Kaye; Stephan Harbarth; Adolf W Karchmer; Yehuda Carmeli Journal: Infect Control Hosp Epidemiol Date: 2005-02 Impact factor: 3.254
Authors: Gabriel K Innes; Pranay R Randad; Anton Korinek; Meghan F Davis; Lance B Price; Anthony D So; Christopher D Heaney Journal: Annu Rev Public Health Date: 2020-01-07 Impact factor: 21.981
Authors: Marta Riu; Pietro Chiarello; Roser Terradas; Maria Sala; Enric Garcia-Alzorriz; Xavier Castells; Santiago Grau; Francesc Cots Journal: PLoS One Date: 2016-04-07 Impact factor: 3.240
Authors: Esabelle Lo Yan Yam; Li Yang Hsu; Eric Peng-Huat Yap; Tsin Wen Yeo; Vernon Lee; Joergen Schlundt; May O Lwin; Direk Limmathurotsakul; Mark Jit; Peter Dedon; Paul Turner; Annelies Wilder-Smith Journal: Antimicrob Resist Infect Control Date: 2019-12-18 Impact factor: 4.887